Hematology-Oncology
Latest news
269 articles · 20 / page
Modernizing AML Trial Eligibility Boosts Enrollment and Equity: Safety-Based Criteria Could Double Participation
Applying safety-focused, modernized eligibility criteria to historical AML trials increased patient eligibility from a median of 48% to 84% and reduced racial/ethnic disparities, suggesting pragmatic pathways to improve enrollment and repre
Ramantamig (JNJ-79635322): A Trispecific T‑Cell Engager Targeting BCMA and GPRC5D Shows Potent Preclinical Activity in Multiple Myeloma
Ramantamig (JNJ-79635322), a trispecific antibody that engages BCMA, GPRC5D and CD3, demonstrates sub-nanomolar cytotoxicity, ex vivo depletion of patient plasma cells, and antitumor activity in xenograft models—supporting ongoing phase 1 t
Fully Human anti-GPRC5D CAR T (RD118) Produces High-Rate, Durable Remissions in Heavily Pretreated Relapsed/Refractory Multiple Myeloma
In a phase 1 study of 18 heavily pretreated patients, the fully human VHH-based anti-GPRC5D CAR T-cell therapy RD118 achieved a 94.4% overall response rate, 72.2% CR/sCR, median PFS 18.2 months, and an acceptable safety profile with predomi
CPX‑351 in Down Syndrome–Associated Myeloid Leukemia: a dose‑sensitivity mismatch that reduced event‑free survival in the ML‑DS 2018 trial
In the ML‑DS 2018 trial, substituting reduced‑intensity induction with CPX‑351 led to lower 24‑month event‑free survival (69% vs 90%) despite excellent overall survival and minimal treatment‑related mortality; MRD by GATA1 NGS, trisomy 8 an
AlloHSCT in Adult Ph– ALL Treated with Pediatric-Inspired GIMEMA LAL1913: MRD Status at Transplant Drives Long-Term Outcomes
Campus ALL real-world data show that pre-transplant MRD negativity after the pediatric-inspired GIMEMA LAL1913 protocol predicts substantially better 3‑year OS and DFS after alloHSCT; MRD-positive patients and those in CR2 fare markedly wor
Age‑Adapted Chemotherapy Plus MRD‑Directed Transplantation Improves Safety Without Sacrificing Efficacy in Ph‑Negative Adult ALL: Key Findings from GRAALL‑2014
The GRAALL‑2014 trial shows that age‑adapted chemotherapy with MRD‑guided alloHSCT reduces early mortality and transplant use while maintaining disease‑free survival in adults (18–59) with Ph‑negative ALL; 4‑year DFS was 57.1% and overall s
Venetoclax Dose Escalation Triggers a Rapid BAFF–BCL-2 Survival Axis in CLL: Implications for Resistance and Combination Strategies
Early venetoclax therapy rapidly induces a BAFF-driven upregulation of prosurvival BCL-2 family proteins in surviving CLL cells, suggesting homeostatic cytokine signaling limits depth and durability of response and identifying BAFF/MCL-1 pa
Venetoclax‑Obinutuzumab in First‑Line CLL: Efficacy Preserved in Unfit Patients — but Dose Intensity Matters
Large trial and real‑world data show fixed‑duration venetoclax‑obinutuzumab delivers high response and durable PFS in fit and unfit CLL patients; maintaining adequate venetoclax dose intensity appears important for MRD and long‑term outcome
Long-term Outcomes in Congenital TTP: Registry Data Show Prophylactic Plasma Reduces Clinical Events but Symptoms and Product Burden Persist
UK registry follow-up of 104 congenital TTP patients shows regular plasma prophylaxis lowers acute episodes and end‑organ events, but residual symptoms and plasma-related issues drive many patients to recombinant ADAMTS13.
DAGO2 (daunorubicin/cytarabine + fractionated gemtuzumab) Outperforms CPX‑351 in Older Adults with Non‑Adverse‑Risk AML: NCRI AML18 Results
In older adults (≥60 years) with non‑adverse‑risk AML enrolled in NCRI AML18, daunorubicin/cytarabine plus fractionated gemtuzumab (DAGO2) produced higher early MRD‑negative CR rates and superior 3‑year EFS and OS versus CPX‑351, with parti
DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18
In NCRI AML18 (n=439, median age 68), DAGO2 produced higher early CR/MRD‑negative rates and superior 3‑year EFS and OS versus CPX‑351 in older adults without adverse‑risk cytogenetics; survival differences persisted across key subgroups inc
Venetoclax plus gilteritinib shows potent preclinical activity in FLT3‑mutant BCL11B‑a lineage‑ambiguous leukemia: translational opportunities and trial design considerations
Preclinical work shows that combining the BCL‑2 inhibitor venetoclax with the FLT3 inhibitor gilteritinib produces deep, reproducible anti‑leukemia activity in FLT3‑mutant, BCL11B‑activated lineage‑ambiguous leukemias. BH3 profiling and sin
Allogeneic HCT in AYA ALL in CR2: MRD-Negativity and Low HCT‑CI Drive Durable Remissions — Dual‑Center Real‑World Outcomes
In 164 adolescents and young adults with ALL transplanted in second remission, 3‑year overall survival was 53% and progression‑free survival 46%. MRD positivity and HCT‑Comorbidity Index >3 predicted worse outcomes; female‑to‑male donor pai
RNA Cancer Vaccines: Revolutionary Advances Bringing Hope for 2029 Clinical Use
RNA cancer vaccines are emerging as powerful tools against hard-to-treat cancers, with breakthroughs in melanoma, pancreatic, and brain cancers showing promise for widespread clinical adoption by 2029.
FDA Clears Second Menin Inhibitor — Ziftomenib (Komzifti) for Relapsed/Refractory NPM1‑Mutated AML
Ziftomenib is FDA-approved for adults with relapsed/refractory NPM1‑mutated AML based on single‑arm KOMET‑001 data showing a 22% remission rate and manageable toxicity including differentiation syndrome; randomized trials are planned to def
DESTINY-Breast04 Consolidated: Trastuzumab Deruxtecan Improves Survival and Maintains Quality of Life in HER2‑Low Metastatic Breast Cancer
DESTINY‑Breast04 shows trastuzumab deruxtecan (T‑DXd) significantly improves progression‑free and overall survival vs physician’s choice chemotherapy in HER2‑low metastatic breast cancer, with manageable safety and preserved patient‑reporte
Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach
In a phase 1 trial, co‑infused autologous CD19- and BCMA-targeting CAR‑T cells produced 80% LLDAS/DORIS remission at 12 weeks in 15 refractory SLE patients, with manageable toxicity and evidence of eradication of autoreactive B‑cell and pla
Allogeneic HCT Rebounds, PTCy Reshapes Donor Choice, and CAR‑T Use Surges: Key Trends from the 2013–2023 CIBMTR Activity Report
CIBMTR’s 2013–2023 registry update shows a 2023 rebound in allogeneic HCT—driven by older adults—widespread adoption of post‑transplant cyclophosphamide (PTCy) across donor types, increasing mismatched donor use, and rapid expansion of comm
Donor CMV Seropositivity Tied to Worse Survival in CMV‑Seronegative AML Patients Undergoing Unrelated HCT with Post‑Transplant Cyclophosphamide
In CMV‑seronegative adult AML recipients receiving unrelated donor hematopoietic cell transplantation with PTCy, donor CMV seropositivity was associated with worse overall survival—primarily through a trend toward higher relapse—supporting
Isolated HLA‑DQB1 Mismatch and Donor Age Do Not Worsen Survival After Unrelated Donor HCT with Post‑Transplant Cyclophosphamide: A Single‑Center Analysis
A single‑center retrospective study of 988 unrelated donor HCTs with PTCy found no significant differences in survival or relapse for isolated HLA‑DQB1 mismatch, 7/8 mismatches, or older donor age; 7/8 mismatch increased severe acute GVHD a
Browse by specialty
Open language-specific specialty feeds and department pages.